Actively Recruiting
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
Led by GlaxoSmithKline · Updated on 2025-12-18
590
Participants Needed
53
Research Sites
137 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of GSK5764227. The study will also see how the levels of GSK5764227 will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab.
CONDITIONS
Official Title
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female participants at least 18 years of age
- Histologically confirmed advanced or metastatic solid tumors
- For monotherapy dose escalation, progressed on or intolerant to all standard therapies
- For combination dose escalation, received three or fewer prior systemic anticancer therapies in advanced/metastatic setting
- At least one target lesion per RECIST 1.1 criteria
- ECOG performance status of 0 or 1 with no recent deterioration
- Adequate organ function
- Provide tumor sample for biomarker analysis if available
- Clinically indicated for at least one of the following: Atezolizumab, durvalumab, or pembrolizumab with cisplatin or carboplatin; Atezolizumab, durvalumab, or pembrolizumab monotherapy; Bevacizumab monotherapy; or Cetuximab monotherapy
- Additional criteria for Chinese participants: born in mainland China, Hong Kong, or Taiwan; descendants of ethnic Chinese parents and grandparents
You will not qualify if you...
- Ongoing adverse reactions from prior therapy not recovered to mild or baseline
- Prior treatment with B7-H3 targeted agents like orlotamab or enoblituzumab
- Primary brain tumor or brain metastasis unless stable and asymptomatic with no steroid use
- Significant cardiac abnormalities including prolonged QTc, severe arrhythmias, or low ejection fraction
- Severe, uncontrolled cardiovascular disorders or serious bleeding or thromboembolic events
- Current or prior interstitial lung disease or pneumonitis requiring high-dose steroids
- Blood donation over 500 mL within one month before study treatment
- Autoimmune disease requiring systemic treatment in past 2 years
- History of bone marrow or solid organ transplant
- Recent immunosuppressive therapy within 30 days before treatment
- Dehydration at screening
- History of nephrotic syndrome or severe proteinuria
- History of serious gastrointestinal fistulas, perforations, abscesses, or bowel obstruction
- Active significant renal conditions requiring dialysis
- For combination therapy, recent systemic anticancer therapy within 28 days before treatment
- Prior severe immune-related adverse events or serious neurologic immune events
- Clinically significant laboratory abnormalities as judged by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 53 locations
1
GSK Investigational Site
Stanford, California, United States, 94063
Actively Recruiting
2
GSK Investigational Site
Denver, Colorado, United States, 80218
Actively Recruiting
3
GSK Investigational Site
New Haven, Connecticut, United States, 06511
Actively Recruiting
4
GSK Investigational Site
Boston, Massachusetts, United States, 02114
Actively Recruiting
5
GSK Investigational Site
Detroit, Michigan, United States, 48201
Actively Recruiting
6
GSK Investigational Site
New Brunswick, New Jersey, United States, 08903
Actively Recruiting
7
GSK Investigational Site
Myrtle Beach, South Carolina, United States, 29572
Actively Recruiting
8
GSK Investigational Site
Nashville, Tennessee, United States, 37203
Actively Recruiting
9
GSK Investigational Site
Austin, Texas, United States, 78705
Actively Recruiting
10
GSK Investigational Site
Dallas, Texas, United States, 75230
Actively Recruiting
11
GSK Investigational Site
San Antonio, Texas, United States, 78229
Actively Recruiting
12
GSK Investigational Site
Tyler, Texas, United States, 75702
Actively Recruiting
13
GSK Investigational Site
West Valley City, Utah, United States, 84119
Actively Recruiting
14
GSK Investigational Site
Norfolk, Virginia, United States, 23502
Actively Recruiting
15
GSK Investigational Site
Rosario, Argentina, S2002
Completed
16
GSK Investigational Site
Viedma, Argentina, R8500ACE
Actively Recruiting
17
GSK Investigational Site
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
18
GSK Investigational Site
Toronto, Ontario, Canada, M5G 1X6
Actively Recruiting
19
GSK Investigational Site
Montreal, Quebec, Canada, H4A 3J1
Actively Recruiting
20
GSK Investigational Site
Sherbrooke, Quebec, Canada, J1H 5N4
Actively Recruiting
21
GSK Investigational Site
Bordeaux, France, 33076
Actively Recruiting
22
GSK Investigational Site
Lyon, France, 69373
Actively Recruiting
23
GSK Investigational Site
Villejuif, France, 94805
Actively Recruiting
24
GSK Investigational Site
Milan, Italy, 20141
Actively Recruiting
25
GSK Investigational Site
Naples, Italy, 80131
Actively Recruiting
26
GSK Investigational Site
Aichi, Japan, 464-8681
Actively Recruiting
27
GSK Investigational Site
Chiba, Japan, 277-8577
Actively Recruiting
28
GSK Investigational Site
Shizuoka, Japan, 411-8777
Actively Recruiting
29
GSK Investigational Site
Tokyo, Japan, 104-0045
Actively Recruiting
30
GSK Investigational Site
Tokyo, Japan, 135-8550
Actively Recruiting
31
GSK Investigational Site
Panama City, Panama
Actively Recruiting
32
GSK Investigational Site
Panama City, Panama
Actively Recruiting
33
GSK Investigational Site
Gyeonggi-do, South Korea, 10408
Actively Recruiting
34
GSK Investigational Site
Seoul, South Korea, 03080
Actively Recruiting
35
GSK Investigational Site
Seoul, South Korea, 03722
Actively Recruiting
36
GSK Investigational Site
Seoul, South Korea, 135-710
Actively Recruiting
37
GSK Investigational Site
Barcelona, Spain, 08035
Actively Recruiting
38
GSK Investigational Site
Barcelona, Spain, 08036
Actively Recruiting
39
GSK Investigational Site
Madrid, Spain, 28034
Actively Recruiting
40
GSK Investigational Site
Madrid, Spain, 28040
Actively Recruiting
41
GSK Investigational Site
Madrid, Spain, 28041
Actively Recruiting
42
GSK Investigational Site
Málaga, Spain, 29010
Actively Recruiting
43
GSK Investigational Site
Changhua, Taiwan, 500
Actively Recruiting
44
GSK Investigational Site
Kaohsiung City, Taiwan, 83301
Actively Recruiting
45
GSK Investigational Site
Taichung, Taiwan, 40447
Actively Recruiting
46
GSK Investigational Site
Tainan, Taiwan, 704
Actively Recruiting
47
GSK Investigational Site
Taipei, Taiwan, 10002
Actively Recruiting
48
GSK Investigational Site
Taipei, Taiwan, 11217
Actively Recruiting
49
GSK Investigational Site
Edinburgh, United Kingdom, EH4 2XU
Actively Recruiting
50
GSK Investigational Site
Glasgow, United Kingdom, G12 0YN
Actively Recruiting
51
GSK Investigational Site
London, United Kingdom, W1G 6AD
Actively Recruiting
52
GSK Investigational Site
London, United Kingdom, WC1E 6AG
Actively Recruiting
53
GSK Investigational Site
Manchester, United Kingdom, M20 4BX
Actively Recruiting
Research Team
U
US GSK Clinical Trials Call Center
CONTACT
E
EU GSK Clinical Trials Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here